Latest Industry News & Trends

Nidek Launches NP-T Preloaded Toric IOL Injector Globally

Japanese ophthalmic company Nidek announced Dec. 2 that it had launched the NP-T preloaded toric intraocular lens (IOL) injection system globally. Previously, the injector had been available only i...

2025-2026 Ophthalmic Meetings Calendar

Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.

Clinical Trial Updates for Ophthalmic Candidates, December 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Lineage Leads Latest Ophthalmic Fundraising with $66 Million Offering

Lineage Cell Therapeutics led recent ophthalmic fundraising efforts with a registered direct offering worth up to $66 million to advance its RPE cell therapy candidate. Financing announced in the p...

CMS Cuts Ophthalmologists’ Procedure Fees, While Raising ASC, HOPD Facility Fees

The Centers for Medicare and Medicaid Services (CMS) published on Nov. 1 the final schedule of Medicare reimbursement fees for physicians in 2025. It also released its facility fee payments for ASC...

Medvisis to Market Clobetasol Drops in Switzerland, Liechtenstein, Under License with Formosa

Swiss company Medvisis has obtained exclusive rights to market clobetasol propionate eye drops in Switzerland and Liechtenstein for inflammation and pain following ocular surgery under a license ag...

Harrow Lowers Price of Drugs through GoodRx Partnership, Price Cuts

Harrow, of Nashville, Tennessee reported Nov. 13 that it had entered into a partnership with GoodRx to provide patients for whom insurance is not a viable option a cash-pay alternative. Harrow prod...

CMS Cuts Ophthalmologists’ Procedure Fees, While Raising ASC, HOPD Facility Fees

The Centers for Medicare and Medicaid Services (CMS) published on Nov. 1 the final schedule of Medicare reimbursement fees for physicians in 2025. It also released its facility fee payments for ASC...

Harrow’s ImprimisRx Unit Gets $34.9 Million Trademark Infringement Verdict

Harrow’s ImprimisRx subsidiary received a $34.9 million verdict on Nov. 20, 2024, in a trademark infringement lawsuit against OSRX Pharmaceuticals, of Missoula, Montana. OSRX is an affiliate of Ocu...

Q3-2024 Ophthalmic Revenue Roundup for Immunocore, Harrow, Tarsus, Lumibird, and Ocular Therapeutix

UK-headquartered Immunocore reported Nov. 6 that its Q3-2024 net revenue from Kimmtrak (tebentafusp) was $80.2 million, a 28 percent increase over $62.6 million in Q3-2023. Regionally, Kimmtrak net...

Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex

Alcon reported Nov. 12 that its Q3-2024 net sales totaled $2.4 billion, a 6 percent increase over $2.3 billion in Q3-2023. Surgical net sales for implantables, consumables, and equipment/other were...

Zeiss Bolsters Launch of Micor 700 at AAO Meeting With US Surgeons Discussing Adoption

Carl Zeiss Meditec featured its Micor 700 at the 2024 meeting of the American Academy of Ophthalmology in Chicago, Illinois, with presentations that included booth talks by select US surgeons who h...

Office-Based Surgery Garners Enthusiasm at 2024 AAO Meeting

Several sessions at the 2024 American Academy of Ophthalmology meeting highlighted the trend of office-based surgery (OBS) and the option of oral sedation among practitioners. The consensus among t...

New Trifocal IOLs Expected to Help the US Resume PC-IOL Growth

Bausch + Lomb’s enVista Envy and J&J Vision’s Odyssey are two new trifocal IOLs that were shown at the 2024 AAO meeting in Chicago. They are expected to help reverse the decline in trifocal IOL sal...

Private Practices Key to US Premium Cataract Surgery Market Dominance

The US represents only 5 percent of the global population in 2024, but it accounts for nearly 36 percent of the world’s premium cataract surgery (PCS) market revenue. The US has the latest premium ...

Clinical Trial Updates for Ophthalmic Candidates, November 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

November 2024 Ophthalmic News Briefs

Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...

Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar

AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...

DÁVI Licenses Clobetasol Propionate Post-op Drops from Formosa for Portugal

Taiwan-based Formosa Pharmaceuticals announced Oct. 31 that it had entered into an exclusive licensing agreement with DÁVI Farmacêutica, of Portugal, for the rights there to market clobetasol propi...

Bausch + Lomb Gains US FDA Approval of enVista Envy Trifocal IOL

Bausch + Lomb reported Oct. 14 that the US FDA had approved itsenVista Envy trifocal intraocular lens. The lens is available on a limited basis in the US and will be launched more broadly in 2025. ...

First ASCRS Business Summit Breaks Down Premium Surgery’s Role in Practice Success

The first-ever ASCRS Business of Refractive Cataract Surgery (BRiCS) Summit was a two-day course designed to equip practices with the knowledge, resources, and confidence to boost their adoption of...

Cure Blindness Project Expands Sight-Saving Care to Six New Countries

Cure Blindness Project is expanding to six new countries—Burundi, Democratic Republic of the Congo, Liberia, Pakistan, Paraguay, and Zambia, the charity reported Oct. 10. Paraguay marksthe charity’...

Lensar Marks 1 Million Procedures Using its Femtosecond Cataract Lasers

Lensar reported Oct. 8 that surgeons had performed more than 1 million procedures using its Lensar femtosecond cataract systems. The Orlando, Florida, company introduced its original Lensar Laser S...

Zeiss Begins Broad US Rollout of Micor 700 for Phaco-less Cataract Surgery

Zeiss Medical Technology reported Sept. 26 that it had begun broad US distribution of the Micor 700, the first hand-held device to extract a crystalline lens in cataract surgery without the need fo...

Eyenovia Launches Clobetasol Drops for Postoperative Pain and Inflammation

Eyenovia announced Sept. 26 the US launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%, known as Clobetasol, for postoperative inflammation and pain following oc...

NEI Researchers Identify Protein That Clears Cataracts in Animals

Researchers at the National Eye Institute (NEI), working with counterparts in China, have discovered a reversible cataract response in hibernating squirrels that may point toward a nonsurgical trea...

Rayner Begins US Study of RayOne Galaxy Trifocal Spiral IOL

UK-based Rayner reported Oct. 1 that the first RayOne Galaxy lenses had been implanted in the US as part of an FDA investigational device exemption (IDE) study. Rayner describes the Galaxy, a trifo...

Eyenovia Launches Clobetasol Drops for Postoperative Pain, Inflammation

Eyenovia announced Sept. 26 the US launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%, known as Clobetasol, for postoperative inflammation and pain following oc...

NEI Researchers Identify Protein That Clears Cataracts in Animals

Researchers at the National Eye Institute (NEI), working with counterparts in China, have discovered a reversible cataract response in hibernating squirrels that may point toward a nonsurgical trea...

Zeiss Announces Broad US Rollout of Micor 700 for Phaco-less Cataract Surgery

Carl Zeiss Meditec reported Sept. 26 that it had begun broad US distribution of the Micor 700, the first hand-held device to extract a crystalline lens in cataract surgery without the need for ultr...

Ophthalmologists Report 0.5 Percent Increase in Q2-2024 Procedure Volume

US ophthalmologists reported that ophthalmic procedures increased 0.5 percent in Q2-2024 compared with the same quarter in 2023, according to Market Scope’s latest survey. Year-over-year performanc...

ONL Leads Latest Ophthalmic Fundraising with $65M Series D Round

ONL Therapeutics led recent ophthalmic fundraising efforts with a $65 million Series D round to continue advancing its small-molecule Fas inhibitor for retinal disease. Financing announced in the p...

Oculis Shuts Down Phase III Trial of OCS-01 Due to Third-Party Administrative Error

Swiss company Oculis reported Aug. 27 in its Q2-2024 financial statement that it was shutting down the Phase III OPTIMIZE-2 trial of its OCS-01 eye drop candidate for postsurgical inflammation and ...

Visiox to Merge with Ocuvex to Advance Two Ophthalmic Drug Candidates

Visiox Pharmaceuticals announced Aug. 19 that it had agreed to merge with Ocuvex Therapeutics, a privately held company in New Hyde Park, New York. A Visiox news release said Ocuvex has a pipeline ...

Precision Lens and Estate of Paul Ehlen to Pay US $12M over Kickbacks

Minnesota-based ophthalmic distributor Precision Lens and the estate of co-founder Paul Ehlen have agreed to pay the US government $12 million to resolve a case involving kickback payments in vario...

Weekly Surgeon Poll, September 2024

Livionex’ Cataract Drop Candidate to Advance After New Analysis of Study Results

A new analysis of 2008 clinical study data has given a boost to Livionex’ topical drop candidate for cataracts, the John Moran Eye Center reported Aug. 16. The drop, called C-KAD, is a formulation ...

Oculis Shuts Down Phase III Trial of OCS-01 Due to Third-Party Administrative Error

Swiss company Oculis reported Aug. 27 in its Q2-2024 financial statement that it was shutting down the Phase III OPTIMIZE-2 trial of its OCS-01 eye drop candidate for postsurgical inflammation and ...

Rayner to Roll Out First Spiral IOL at 2024 ESCRS Congress

UK-based Rayner reported Aug. 26 that it was set to launch the first spiral intraocular lens models—the RayOne Galaxy and Galaxy Toric—at the 2024 ESCRS Congress, set for Sept. 6-10 in Barcelona, S...

Alcon Reports Q2-2024 Net Sales of $2.5 Billion

Alcon reported Aug. 20 that its Q2-2024 net sales totaled $2.5 billion, a record quarter for the company and a 3 percent increase (+6 percent cc) over $2.4 billion in Q2-2023. Surgical net sales fo...

Precision Lens and Estate of Paul Ehlen to Pay US $12M over Kickbacks

Minnesota-based ophthalmic distributor Precision Lens and the estate of co-founder Paul Ehlen have agreed to pay the US government $12 million to resolve a case involving kickback payments in vario...

Livionex’ Cataract Drop Candidate to Advance After New Analysis of Study Results

A new analysis of 2008 clinical study data has given a boost to Livionex’ topical drop candidate for cataracts, the John Moran Eye Center reported Aug. 16. The drop, called C-KAD, is a formulation ...

Steady Growth Expected in Single-Use Surgical Products, Even With Push to Cut OR Waste

Environmental sustainability programs have grown in scope over the last five years, with major ophthalmic surgery associations joining forces to propose specific actions to reduce the carbon footpr...

Private Equity Ownership of Surgery Centers Continues to Gain Share, Survey Shows

Private equity (PE) investment in ophthalmic practices continues to expand, even as debates over the pros and cons of these investments increase, too. For some practices that were hit hard by COVID...

Lensar Ends Collaboration with Oertli for Phaco Portion of Ally Cataract System

Lensar has terminated its collaboration agreement with Swiss company Oertli, according to a filing Aug. 5 with the US Securities and Exchange Commission. The two had been developing the Ally Adapti...

Select US FDA Approvals and Clearances in July 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in July 2024, according to the agency’s database. Topcon gained clearance for its Maestro2 OCT in c...

Meet with Market Scope at the 2024 ESCRS Congress

Market Scope will be exhibiting at the 2024 ESCRS congress, which is Sept. 6-10 in Barcelona, Spain. We will be located at Stand 6.D12. Contact us to set up a time to discuss any custom research ne...

Renowned Charity HCP Cureblindness Rebrands as Cure Blindness Project

HCP Cureblindness has rebranded as the Cure Blindness Project, the group announced July 29. The move is designed to better reflect the eye charity’s expanded geographical footprint and commitment t...

Q2-2024 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Amgen, STAAR, Astellas, Immunocore, Tarsus, Biogen, Lensar, and Iridex

AbbVie, of North Chicago, Illinois, reported July 25 that Q2-2024 net revenue for its eye care products totaled $533 million, a 13.3 percent decline (-10.9 percent cc) from $617 million in Q2-2023....

Lensar Ends Collaboration with Oertli for Phaco Portion of Ally Cataract System

Lensar has terminated its collaboration agreement with Swiss company Oertli, according to a filing Aug. 5 with the US Securities and Exchange Commission. The two had been developing the Ally Adapti...

Q2-2024 Ophthalmic Revenue Roundup for Hoya, Harrow, RxSight, Sight Sciences, Ocular Therapeutix, and EyePoint

Japan-based Hoya Corporation announced Aug. 1 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2024—the first quarter of its fiscal year...

Formosa Licenses Clobetasol Propionate Drops to Apotex for Canada

Taiwan-based Formosa Pharmaceuticals announced Aug. 5 that it had agreed to license to Apotex exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inflammation and pain...

HCP Cureblindness Rebrands as Cure Blindness Project

HCP Cureblindness has rebranded as the Cure Blindness Project, the group announced July 29. The move is designed to better reflect the eye charity’s expanded geographical footprint and commitment t...

Select US FDA Approvals and Clearances in June 2024

The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in June 2024, according to the agency’s database. Alcon gained clearance for its much-anticipated ...

Medicare Advantage Insurers Make Millions Off Ophthalmic Diagnoses They Add to Patient Records, WSJ Reports

Private insurers involved in the US Medicare Advantage program added hundreds of thousands of questionable diagnoses, including those for diabetic cataracts, to patient records in recent years to b...

MST Offers Diamond Knife Subscription Service in Move to Curb Waste

MicroSurgical Technology (MST) has launched a diamond knife subscription service for US ophthalmologists. The Redmond, Washington, company kicked off the service in April at the 2024 meeting of the...

Weekly Surgeon Poll, July 2024

Medicare Advantage Insurers Make Millions Off Ophthalmic Diagnoses They Add to Patient Records, WSJ Reports

Private insurers involved in the US Medicare Advantage program added hundreds of thousands of questionable diagnoses, including those for diabetic cataracts, to patient records in recent years to b...

J&J Vision Generates Q2-2024 Surgical Revenue of $367 Million

J&J Vision’s Q2-2024 global surgical revenue totaled $367 million, a 0.5 percent decrease (1.2 percent increase in constant currency) from $369 million in Q2-2023, parent Johnson & Johnson, of New ...

Ophthalmology Chain Clínica Baviera Enters UK Market with Acquisition of Optimax

European ophthalmology chain Clínica Baviera has extended its reach into the UK with the purchase of Optimax. Optimax (Eye Hospitals Group and subsidiaries) operates 19 clinics under the Optimax an...

Alcon Gains US FDA 510(k) Clearance for Unity VCS and CS Systems

Alcon reported June 24 that itsUnity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) had received US FDA 510(k) clearance. The company said it would be seeking real-world feedbac...

Innovations on Horizon are Expected to Rejuvenate Cataract Equipment Market

Signs of innovation and renewal can be found in all segments of the cataract equipment market, despite evidence that the market has become mature. Innovation looms in next-generation ultrasonic pha...

Clinical Trial Updates for Ophthalmic Candidates, June 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Surgeons, Societies Respond to MACs’ New Proposed MIGS Limits

Surgeons and ophthalmic societies worked together at open meetings in June to address five Medicare administrative contractors’ latest proposal to limit coverage of minimally invasive glaucoma surg...

June 2024 Ophthalmic News Briefs

Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...

MST Offers Diamond Knife Subscription Service in Move to Curb Waste

MicroSurgical Technology (MST) has launched a diamond knife subscription service for US ophthalmologists. The Redmond, Washington, company kicked off the service in April at the 2024 meeting of the...

Co-founder of HCP Cureblindness to Step Down as Board Chair, Remain Active with Charity

HCP Cureblindness, formerly known as the Himalayan Cataract Project, reported June 11 that co-founder Geoff Tabin, MD, will step down as board chair but maintain an active role with the charity as ...

WPS MAC Revisits Changing Coverage for Cataract Surgery

WPS Insurance Corporation, a Medicare administrative contractor (MAC) in the US, has again proposed changing its coverage of cataract surgery after putting forth a similar proposal in September 202...

Nidek Gains CE Marking for Preloaded IOL Injector System

Japan’s Nidek announced June 10 that it had received CE marking for the NP-1/NP-1C preloaded IOL injection system. The system is preloaded with the Aktis aspheric hydrophobic soft acrylic lens, whi...

Q1-2024 Ophthalmic Revenue Roundup for Amgen, Hoya, and Immunocore

Amgen, of Thousand Oaks, California, reported May 2 that its Q1-2024 revenue from Tepezza was $424 million. The total consisted of $419 million in the US and $5 million outside the US. The company ...

Bausch + Lomb Receives Health Canada Approval for EnVista Envy Trifocal IOL

Bausch + Lomb announced May 28 that Health Canada had approved the enVista Envy trifocal intraocular lens (IOL). It’s the first approval for the new lens. The Envy is expected to be available in Ca...

Champalimaud Vision Award Recognizes Eye Hospital Serving Gaza and West Bank

A sparsely attended Champalimaud Vision Award Lecture at the 2024 ARVO meeting highlighted the work of St. John of Jerusalem Eye Hospital in Gaza, Jerusalem, and the West Bank. Leonor Beleza, presi...

2024 ARVO Meeting Sets Attendance Record, Showcases Novel Treatment Approaches

The 2024 meeting of the Association for Research in Vision and Ophthalmology set a record as the largest ARVO meeting ever. The 11,631 registered attendees passed the old record of 10,224 set in Va...

Seattle and Phoenix Among top US Metros for Potential Growth in Premium IOL Surgery

US cataract procedures in general are driven by the over-65 population, but the premium surgery rate is fueled by a subset of comparatively affluent and healthy adults within this population. Under...

RxSight Leads Latest Ophthalmic Fundraising with $115 Million Public Offering

RxSight led recent ophthalmic fundraising efforts with a $115 million public offering to continue commercialization of its Light Adjustable Lens portfolio. Financing announced in the past four week...

Clinical Trial Updates for Ophthalmic Candidates, May 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

May 2024 Ophthalmic News Briefs

Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...

Formosa Licenses Clobetasol Propionate Drops to Tabuk Pharmaceuticals for MENA Region

Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...

Q1-2024 Ophthalmic Revenue Roundup for Apellis, STAAR, RxSight, Tarsus, Sight Sciences, and Three Others

Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 that its Q1-2024 US net product revenue for Syfovre was $137.5 million, compared with $18.4 million in Q1-2023. Syfovre gained US ...

Q1-2024 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, and Lumibird

Bausch + Lomb reported May 1 that its Q1-2024 revenue was $1.1 billion, an 18 percent increase (+20 percent cc) over $931 million in Q1-2023. Vision Care segment revenue in Q1-2024 was $635 million...

New Products Set Upbeat Tone for ASCRS Meeting; Attendance Remains a Concern

New product launches created high surgeon interest at the 2024 meeting of the American Society of Cataract and Refractive Surgery (ASCRS), but the overall mood of the conference was tempered somewh...

Researchers in Georgia Establish Database of Proteins in Aqueous Humor to Advance Vision Research

The National Eye Institute (NEI) announced April 8 that researchers from the Medical College of Georgia at Augusta University had established a database of the proteins found in the eye’s aqueous h...

Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements

Retinal drug developer Outlook Therapeutics led recent ophthalmic fundraising efforts with two private placements, for proceeds totaling $164 million. Financing announced in the past four weeks tot...

ASCRS Marks 50 Years with Look Back at Cataract Surgery in 1974

The ASCRS commemorated its 50th anniversary at its 2024 annual meeting by re-creating an ophthalmologist’s office and surgery suite from the 1970s in the exhibit hall. The display served as a remin...

J&J Vision Launches Tecnis Odyssey PC-IOL at 2024 ASCRS Meeting

Johnson & Johnson Vision launched and touted the Tecnis Odyssey presbyopia-correcting IOL at a number of venues at the 2024 ASCRS meeting. Blake Williamson, MD, and Priya Matthews, MD, described J&...

RxSight Launches the LAL+ IOL with Large ASCRS Program

RxSight continued to build momentum for its post-op adjustable IOL with a big presence at the 2024 ASCRS meeting, including an Eyecelerator presentation on the new LAL+ and 14 speaker sessions at t...

Rayner and Carl Zeiss Meditec Display Recently Acquired Phaco Machines

The US ultrasonic cataract machine market has been dominated by Alcon, Bausch + Lomb, and Johnson & Johnson for more than a decade, so it’s unusual to learn of a new phaco machine being launched by...

Dry Eye Screening Before Surgery Seems Logical, but Hurdles Remain

The need to continue lobbying for dry eye evaluation prior to patients undergoing anterior segment surgery is somewhat baffling. Such testing seems like an obvious approach for the many patients wh...

BVI Medical Launches Podeye Hydrophobic Monofocal IOL in Japan

BVI Medical announced April 17 that it had launched its Podeye hydrophobic monofocal IOL in Japan, following approval by the Japanese Pharmaceuticals and Medical Devices Agency. The lens was set to...

Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid

Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...

Weekly Surgeon Poll, April 2024

BVI Medical Launches Podeye Hydrophobic Monofocal IOL in Japan

BVI Medical announced April 17 that it had launched its Podeye hydrophobic monofocal IOL in Japan, following approval by the Japanese Pharmaceuticals and Medical Devices Agency. The lens was set to...

J&J Vision Reports Q1-2024 Surgical Revenue of $348 Million

J&J Vision’s Q1-2024 global surgical revenue totaled $348 million, up 0.3 percent (+1.1 percent cc) over $347 million in Q1-2023, parent Johnson & Johnson, of New Brunswick, New Jersey, reported Ap...

Japanese IOL Maker Hoya Halts Production After Cyberattack

Japanese intraocular lens maker Hoya reported on April 4 that production of several of its products had stopped after a computer system failure, “most likely caused by unauthorized access” to its s...

Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid

Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...

Rayner Marks Sale of 5 Millionth RayOne IOL

UK-based Rayner reported April 3 that it had sold its 5 millionth RayOne lens and 11 millionth lens made from RayAcryl, Rayner’s proprietary hydrophilic acrylic material. Rayner, founded in 1910, r...

Alcon Appoints Terry Kim, MD, as CMO, Head of Global Medical Safety

Alcon announced March 26 that Terry Kim, MD, would join the company in April as chief medical officer (CMO) and head of global medical safety. Kim, who specializes in cornea, cataract, and refracti...

Rayner Updates Packaging to Lessen Impact on Environment

UK-based Rayner announced March 25 that it would update its packaging to reduce the company’s carbon footprint and improve ease of use for customers. Rayner said the new packaging will replace pape...

Alcon Launches Clareon PC-IOLs in India

Alcon announced March 12 that it had launched presbyopia-correcting intraocular lenses (IOLs) in India made of the Clareon glistening-free material. The Clareon platform is available in India in tw...

Ophthalmologists Report 1.8 Percent Decline in Q4-2023 Procedure Volume

----- Refractive: -12.1 IOL: 5.4 Glaucoma: 4.8 Retina: -4.4 ----- US ophthalmologists reported that ophthalmic procedures decreased 1.8 percent in Q4-2023 compared with the same quarter in 2022, ac...

Robust Premium IOL Revenue Growth Expected to Continue Through 2029

The global intraocular lens market has shown strong growth during the past seven years, increasing from $3.8 billion in 2017 to $5.8 billion in 2023, for a compound annual growth rate of nearly 8 p...

US FDA Approves Clobetasol Propionate Eye Drops for Postsurgical Pain, Inflammation

Taiwan-based Formosa Pharmaceuticals announced March 4 that the US FDA had approved clobetasol propionate ophthalmic suspension 0.05% (APP13007) for inflammation and pain following ocular surgery. ...

Select US FDA Approvals and Clearances in February 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in February 2024, according to the agency’s database. CATS Tonometer received clearance for its ton...

Alcon’s Vivity EDOF IOL Reaches Milestone of 1 Million Implantations

Alcon reported March 6 that the AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) had surpassed more than 1 million implantations worldwide. According to...

Meet with Market Scope at the 2024 ASCRS Meeting

Market Scope will be located at Booth 3080 at the 2024 ASCRS meeting in Boston, set for April 5-8. Contact us to set up a time to discuss your custom research needs and to learn about our new repor...

2023 Ophthalmic Revenue Roundup for Sight Sciences and Ocular Therapeutix

Sight Sciences reported March 7 that it generated 2023 total revenue of $81.1 million, an increase of 14 percent over $71.3 million in 2022. Surgical glaucoma revenue in 2023 was $74.3 million, a 1...

NovaBay, Eyenovia Team Up to Co-promote Ophthalmic Products

Eyenovia and NovaBay Pharmaceuticals announced March 13 the signing of a co-promotion agreement to commercialize their prescription ophthalmic products. Under the agreement, NovaBay will market Eye...

Alcon’s Vivity EDOF IOL Reaches Milestone of 1 Million Implantations

Alcon reported March 6 that the AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) had surpassed more than 1 million implantations worldwide. According to...

US FDA Approves Clobetasol Propionate Eye Drops for Postsurgical Pain, Inflammation

Taiwan-based Formosa Pharmaceuticals announced March 4 that the US FDA had approved clobetasol propionate ophthalmic suspension 0.05% (APP13007) for inflammation and pain following ocular surgery. ...

VSY Launches Enova Maestro Trifocal Toric Preloaded IOL at ESCRS Winter Meeting

Germany’s VSY Biotechnology launched its Enova Maestro trifocal toric preloaded intraocular lens (IOL) at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting, held Feb. ...

Regulators in Singapore Accept NDA from AffaMed for Dextenza

Shanghai-based AffaMed Therapeutics announced Feb. 19 that the Singapore Health Sciences Authority had accepted its new drug application (NDA) for Dextenza (0.4 mg dexamethasone intracanalicular in...

MAC Drops Plan to Require Visual Acuity of 20/50 or Worse for Cataract Surgery

Wisconsin Physician Services (WPS), a Medicare Administrative Contractor (MAC) in the US, has abandoned a proposal to require visual acuity of 20/50 or worse for cataract surgery to be medically ne...

Johnson & Johnson MedTech Launches Tecnis PureSee PC-IOL in EMEA Countries

Johnson & Johnson MedTech announced Feb. 15 that its Tecnis PureSee refractive presbyopia-correcting intraocular lens (IOL) is now available in select markets in Europe, the Middle East, and Africa...

February 2024 Weekly Surgeon Poll: US vs. Western European Ophthalmologists

February 2024 Ophthalmic News Briefs

Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...

Johnson & Johnson MedTech Launches Tecnis PureSee PC-IOL in Select EMEA Countries

Johnson & Johnson MedTech announced Feb. 15 that its Tecnis PureSee refractive presbyopia-correcting intraocular lens (IOL) is now available in select markets in Europe, the Middle East, and Africa...

Omeros Changes Up Royalty Agreement with DRI Healthcare for Additional $115 Million

Seattle-based Omeros reported Feb. 1 that it had changed up its agreement with DRI Healthcare Trust for Omidria royalties. DRI, based in Toronto, Canada, has paid Omeros an additional $115 million ...

Keranova Appoints Denise Hoblingre as CEO

France’s Keranova recently announced that Denise Hoblingre had been appointed chief executive officer. She succeeds company co-founder Fabrice Romano, DVM. Hoblingre joined Keranova at its inceptio...

MAC Drops Plan to Require Visual Acuity of 20/50 or Worse for Cataract Surgery

Wisconsin Physician Services (WPS), a Medicare Administrative Contractor (MAC) in the US, has abandoned a proposal to require visual acuity of 20/50 or worse for cataract surgery to be medically ne...

Ophtec Launches Its Precizon Go Enhanced Monofocal Lens

Dutch company Ophtec announced Dec. 11 the launch of its Precizon Go intraocular lens (IOL), a “monofocal plus” lens designed to provide distance and enhanced intermediate vision. Precizon Go featu...

Clinical Trial Updates for Ophthalmic Candidates, January 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

US FDA PDUFA Target Action Dates for Ophthalmic Candidates, 2024

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic prescription and biologic drug candidates and those classified as drug/device combin...

January 2024 Ophthalmic News Briefs

Maker of Sophi Phaco Machines UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sop...

Rayner Acquires Switzerland-Based This AG, Maker of Sophi Phaco Machines

UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sophi phaco machines are battery-...

Centricity’s Leonard Borrmann, PharmD, to Succeed Rob Thornhill as CEO

Centricity Vision, of Carlsbad, California, announced Dec. 20 that Leonard Borrmann, PharmD, formerly the company’s head of research and development, had been named chief executive officer. Borrman...

Ophthalmic Drugmaker Visiox to Merge with SPAC to Gain Nasdaq Listing

Privately held Visiox Pharmaceuticals reported Dec. 27 that it will gain a listing on the Nasdaq through a merger with PowerUp Acquisition Corp., a special purpose acquisition company (SPAC) based ...

HelpMeSee Wins Award for its Cataract Surgery Training Simulator

HelpMeSee, a global nonprofit group that provides simulation training in low-cost cataract surgery, announced that it had received the 2023 Modeling and Simulation Award from the National Training ...

Ophtec Launches Precizon Go Enhanced Monofocal IOL

Dutch company Ophtec announced Dec. 11 the launch of its Precizon Go intraocular lens (IOL), a “monofocal plus” lens designed to provide distance and enhanced intermediate vision. Precizon Go featu...

Carl Zeiss Meditec Acquires DORC for $1.1 Billion

Carl Zeiss Meditec announced Dec. 15 that it had agreed to acquire Netherlands-based Dutch Ophthalmic Research Center (DORC) from investment firm Eurazeo, of Paris. DORC, founded in 1983, is a lead...

Ophthalmic Company Revenue Increases 3.4 Percent in Third Quarter of 2023

Ophthalmic manufacturer revenue in Q3-2023 totaled $11.1 billion. Revenue increased 3.4 percent from the same quarter in 2022 and decreased 2.7 percent from Q2-2023. The total includes Market Scope...

MAC WPS Proposes Limiting Cataract Surgery to Those with 20/50 or Worse Visual Acuity

Wisconsin Physician Services (WPS), a Medicare Administrative Contractor (MAC) in the US, has proposed requiring visual acuity of 20/50 or worse for cataract surgery to be medically necessary and p...

Patients Blinded After Fungal Infections Mar Free Eye Surgery Event in Brazil

A free ophthalmic surgery event in northern Brazil in September was tarnished when 104 of 141 pa-tients—nearly 74 percent—suffered serious postoperative complications from fungal endophthalmitis. T...

Weekly Surgeon Poll, December 2023

December 2023 Ophthalmic News Briefs

Enzene Biosciences, based in Pune, India, announced in November that it had launched a ranibizumab biosimilar for the treatment of wet age-related macular degeneration (AMD). The product references...

MAC WPS Proposes Limiting Cataract Surgery to Those with 20/50 or Worse Vision

Wisconsin Physician Services (WPS), a Medicare Administrative Contractor (MAC) in the US, has proposed requiring visual acuity of 20/50 or worse for cataract surgery to be medically necessary and p...

US FDA Gives Green Light to Phase II Trial of VivaVision’s Candidate for Post-Cataract Inflammation

VivaVision, of Wenzhou, China, announced Dec. 4 that the US FDA had cleared a Phase II trial of its VVN461 eye drop candidate for postoperative inflammation after cataract surgery. VVN461 is a pote...

Patients Blinded After Fungal Infections Mar Free Eye Surgery Event in Brazil

A free ophthalmic surgery event in northern Brazil in September was tarnished when 104 of 141 patients—nearly 74 percent—suffered serious postoperative complications from fungal endophthalmitis. Th...

SpyGlass Pharma Appoints Margot Goodkin, MD, PhD, as Chief Medical Officer

SpyGlass Pharma announced Dec. 5 that it had appointed Margot Goodkin, MD, PhD, as chief medical officer. Goodkin is a glaucoma fellowship-trained ophthalmologist and biopharmaceutical industry vet...

Pros and Cons of Same-Day Cataract Surgery Debated During AAO Refractive Day

The advantages and disadvantages of immediate sequential bilateral cataract surgery (ISBCS) took center stage during a 2023 AAO Refractive Day session that tasked Rupert Menapace, MD (Austria), wit...

Oertli Files for US FDA 510(k) Clearance for Phaco Portion of Lensar Ally System

Lensar and Swiss company Oertli announced Oct. 30 that Oertli had filed for US FDA 510(k) clearance for its Faros easyPhaco phacoemulsification system. If cleared, the Faros will be integrated into...

US Dominance of Premium Cataract Surgery Market Expected to Grow

New technology and competition are expected to further expand the dominance of the US premium cataract surgery (PCS) market over the next five years. The US is already the dominant PCS market globa...

RxSight Announces Controlled Launch of LAL+ with Extended EDOF Functionality

RxSight—already the fastest growing IOL company in the US—is conducting a controlled launch of an additional version of the Light Adjustable Lens (LAL), referred to as the LAL+. Stephen Slade, MD, ...

Surgeons Compare Trifocal and EDOF IOLs During AAO Refractive Day

Trifocal IOLs went head-to-head with extended depth of focus lenses during the 2023 AAO Refractive Day program as Damien Gatinel, MD, PhD (France), advocated for trifocal models and Douglas Koch, M...

Diagnostic Leaders Showcase Devices, Collaborations at AAO Meeting

Notable diagnostic innovations showcased at the 2023 meeting of the American Academy of Ophthalmology were Topcon’s Tempo perimeter and Heidelberg Engineering’s Anterion anterior OCT platform. Also...

Bausch + Lomb Launches enVista Aspire Intermediate-Optimized Monofocal and Toric IOLs in US

Bausch + Lomb announced Oct. 18 the US launch of its enVista Aspire monofocal and toric intraocular lenses with intermediate-optimized optics. The company said that, unlike conventional spherical m...

Q3-2023 Ophthalmic Revenue Roundup for Immunocore, Harrow, RxSight, and Three Others

UK-headquartered Immunocore reported Nov. 7 that its Q3-2023 net revenue from Kimmtrak (tebentafusp) was £49.7 million ($60.7 million, converted at a rate of £1.00 to $1.2214), an increase of 9 per...

Oertli Files for US FDA 510(k) Clearance for Phaco Portion of Lensar Ally System

Lensar and Swiss company Oertli announced Oct. 30 that Oertli had filed for US FDA 510(k) clearance for its Faros easyPhaco phacoemulsification system. If cleared, the Faros will be integrated into...

Bausch + Lomb Launches SeeNa Optical Biometry and Topography System in the US

Bausch + Lomb announced on Oct. 30 the US launch of its SeeNa ophthalmic diagnostic system for refractive cataract patients, designed for integration with the company’s Eyetelligence surgical plann...

Bausch + Lomb Launches enVista Aspire Intermediate-Optimized Monofocal and Toric IOLs in US

Bausch + Lomb announced Oct. 18 the US launch of its enVista Aspire monofocal and toric intraocular lenses with intermediate-optimized optics. The company said that, unlike conventional spherical m...

Buzzworthy Topics at the 2023 ESCRS Congress

Minimally Invasive Glaucoma Surgery (MIGS): The ESCRS highlighted the growing importance of MIGS this year by holding the meeting’s first MIGS master class. Several speakers in other sessions extol...

October 2023 Ophthalmic News Briefs

Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...

Weekly Surgeon Poll, October 2023

US FDA Clears Anterion Anterior Segment Diagnostic Platform from Heidelberg

Heidelberg Engineering announced Oct. 13 that the US FDA had cleared its Anterion diagnostic platform for the anterior segment. The system gained CE marking in 2018. The Anterion combines biometry,...

HumanOptics Appoints Alexander Berka as New CEO

HumanOptics, of Erlangen, Germany, announced Oct. 4 that it had named Alexander Berka as its chief executive officer. HumanOptics markets an artificial iris and the Triva, Torica, and Aspria intrao...

HelpMeSee Appoints Bonnie An Henderson, MD, as President and CEO

HelpMeSee, a global nonprofit group that provides simulation training in low-cost cataract surgery, announced Oct. 10 that it had named Bonnie An Henderson, MD, as president and chief executive off...

Melt Gains Exclusive License to Catalent’s Fast-Dissolve Technology with Certain Sedation Ingredients

Melt Pharmaceuticals announced Sept. 26 that it had entered into an exclusive development and license agreement with Catalent to use Catalent’s Zydis orally disintegrating tablet with MELT-300, a s...

Mati Completes Facility to Manufacture Evolute Punctal Plug Portfolio

Mati Therapeutics, of Austin, Texas, reported Sept. 12 that it had completed a 10 thousand square foot facility in Bryan, Texas, to manufacture the company’s Evolute sustained drug delivery platfor...

2023 ESCRS Congress Pits Greener Choices Against Traditional Practices to Fight Waste

Eye surgeons swapped their scrubs for boxing robes at the 2023 congress of the European Society of Cataract and Refractive Surgeons, as they took part in the society’s high-profile battle against s...

FDA Warns Eight Companies Over Marketing Unapproved or Unsafe Eye Drops in the US

The US FDA reported Sept. 12 that it had issued warning letters to eight companies for manufacturing or marketing unapproved eye drug products, expanding the list of companies that the FDA has targ...

Brim Leads Latest Ophthalmic Fundraising with $45.8 Million Rights Issue

Brim Biotechnologies, of Taiwan, led recent ophthalmic fundraising efforts with a $45.8 million rights issue to advance its lead dry eye candidate. Funding announced in the past four weeks totaled ...

FDA Warns Eight Companies Over Marketing Unapproved Eye Drops

The US FDA reported Sept. 12 that it had issued warning letters to eight companies for manufacturing or marketing unapproved eye drug products, expanding the list of companies that the FDA has targ...

ESCRS and ASCRS Target Single-Use Surgical Devices in Bid to Reduce OR Waste

There is growing concern among the world’s largest ophthalmic surgical societies over the environmental impact of operating-room (OR) waste generated annually by the world’s 47 million ophthalmic s...

US FDA Approves Generic Bromfenac Drops from India’s Lupin for Postsurgical Pain and Inflammation

Indian drugmaker Lupin announced Aug. 16 that the US FDA had approved its abbreviated new drug application for bromfenac ophthalmic solution, 0.09%, a generic equivalent of Bausch + Lomb’s Bromday....

Select US FDA Device Approvals and Clearances in July 2023

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in July 2023, according to the agency’s database. Altris received clearance for its image managemen...

Kriya Leads Latest Ophthalmic Fundraising with $150 Million in Series C

Kriya Therapeutics led recent ophthalmic fundraising efforts with $150 million in a Series C financing to advance its gene therapy candidates. Funding announced in the past four weeks totaled $456....

Clinical Trial Updates for Ophthalmic Candidates, August 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

CMS Proposes Cut in 2024 Physician Payments, Increase in Facility Fees

The Centers for Medicare and Medicaid Services (CMS) is proposing to cut the conversion factor for the Physician Fee Schedule (PFS)—one of four factors used in calculating Medicare payments to doct...

August 2023 Ophthalmic News Briefs

New York’s Icahn School of Medicine at Mount Sinai announced July 5 that it had launched the Center for Ophthalmic Artificial Intelligence and Human Health. The center will incorporate AI into educ...

Q2-2023 Ophthalmic Revenue Roundup for Alcon, Immunocore, Harrow, and Two Others

Alcon reported Aug. 15 that its Q2-2023 net sales totaled $2.4 billion, a 9 percent increase (+12 percent cc) over $2.2 billion in Q2-2022. Surgical net sales for implantables, consumables, and equ...

CMS Proposes Cut in 2024 Physician Payments, Increase in Facility Fees

The Centers for Medicare and Medicaid Services (CMS) is proposing to cut the conversion factor for the Physician Fee Schedule (PFS)—one of four factors used in calculating Medicare payments to doct...